AUA releases updated BPH guideline addressing new treatments
In this interview, Steven A. Kaplan, MD, highlights the key updates to the 2018 guideline that differentiates it from the AUA’s 2010 guideline on this topic.
A new AUA guideline on the management of lower urinary tract symptoms due to BPH focuses on surgical treatments, including newer minimally invasive procedures. In this interview, Steven A. Kaplan, MD, highlights the key updates to the 2018 guideline that differentiates it from the AUA’s 2010 guideline on this topic.
Dr. Kaplan, of the Icahn School of Medicine at Mount Sinai in New York and a member of the panel that developed the guideline, discusses new FDA-approved therapies, one treatment that is no longer recommended, and the use of imaging to make a proper diagnosis prior to treatment. He was interviewed by Urology Times Content Channel Director Richard R. Kerr.
Dr. Kaplan is a consultant/adviser to Astellas, ProVerum Medical, ProArc, Zenflow, Serenity, Allium, Avadel, and Nymox and serves in a leadership position for Medivizor, EcoFusion, and AvantCourse.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
